Key points from article :
Circulate Health, a company focused on longevity and environmental health, has secured a seven-figure strategic investment from Scrum Ventures to scale its Therapeutic Plasma Exchange (TPE) technology. The funding will support the company’s push to make TPE a more accessible, patient-centred approach to proactive health and anti-aging care, building on growing interest in interventions that go beyond treating disease to maintaining long-term health. No lead author or scientific journal is associated with this announcement, which is a company release.
At the heart of Circulate Health’s approach is TPE, a medical procedure that removes a patient’s plasma and replaces it with a clean substitute, allowing harmful substances to be filtered out of the bloodstream. The company’s platform is designed to remove microplastics, environmental toxins, inflammatory markers, and other microscopic pollutants that researchers suspect may contribute to chronic inflammation, oxidative stress, and age-related health problems.
Often described as an “oil change” for the blood, TPE has been shown in clinical contexts to clear toxins such as heavy metals, mold, and certain viruses, reduce neurotoxic proteins like beta-amyloid, and remove autoantibodies involved in autoimmune conditions. Circulate Health hypothesises that these effects could help “reset” inflammatory signalling and counter processes linked to biological ageing.
According to CEO and co-founder Brad Younggren, consumer awareness of TPE’s potential benefits is growing rapidly. The investment from Scrum Ventures follows a $12 million seed round led by Khosla Ventures earlier in 2025 and highlights the increasing overlap between longevity science and environmental health as areas of both scientific and commercial interest.
